使用FDA不良事件报告系统对强制维多酮进行药物警戒性评价

{"title":"使用FDA不良事件报告系统对强制维多酮进行药物警戒性评价","authors":"","doi":"10.5246/jcps.2023.02.011","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":15329,"journal":{"name":"Journal of Chinese Pharmaceutical Sciences","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Pharmacovigilance evaluation of enfortumab vedotin using the FDA Adverse Event Reporting System\",\"authors\":\"\",\"doi\":\"10.5246/jcps.2023.02.011\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":15329,\"journal\":{\"name\":\"Journal of Chinese Pharmaceutical Sciences\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-02-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Chinese Pharmaceutical Sciences\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.5246/jcps.2023.02.011\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Chinese Pharmaceutical Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5246/jcps.2023.02.011","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}